Advances in Therapy

, Volume 29, Issue 1, pp 14–25 | Cite as

DPP-4 Inhibitors and Lipids: Systematic Review and Meta-Analysis

  • Matteo Monami
  • Caterina Lamanna
  • Carla Maria Desideri
  • Edoardo Mannucci
Review

Abstract

Introduction

Lipid profile is an important determinant of cardiovascular risk in type 2 diabetic patients. Available glucose-lowering agents can affect lipid levels. Dipeptidyl peptidase-4 (DPP-4) inhibitors have been reported to reduce total cholesterol, but results are inconsistent across trials. The present metaanalysis was designed to assess the effect of DPP-4 inhibitors on blood lipids, verifying possible differences across compounds of this class.

Methods

An extensive search of Medline and the Cochrane Library (any date up to December 31, 2010, restricted to randomized clinical trials, published in English) was performed for all trials containing, in any field, the words “sitagliptin,” “vildagliptin,” “saxagliptin,” “alogliptin,” “linagliptin,” and/or “dutogliptin.” Completed but unpublished trials were identified through a search of the ClinicalTrials.gov website, using the same keywords as above. Differences in the endpoint levels and absolute or percent variations of lipids were assessed. A metaregression was performed on the trials specified above to assess the effect of putative moderators on the effect of DPP-4 inhibitors on plasma lipids, considering all drugs together and each one separately.

Results

Although the number of trials of appropriate size and duration was high (n=53), only a small fraction of those (n=17) reported data on endpoint total, high-density lipoprotein, and low-density lipoprotein cholesterol, and triglyceride. The difference-in-means for endpoint versus baseline total cholesterol in patients on DPP-4 inhibitors treatment was significantly higher in comparison with controls, meaning that treatment with DPP-4 inhibitors is associated with a significant reduction in total cholesterol (−0.18 [−0.29; −0.06] mmol/L (−7.0 [−11.2; −2.50] mg/dL); P=0.002).

Conclusions

This meta-analysis suggests a possible beneficial effect of DPP-4 inhibitors on cholesterol, which, although small, could contribute to the reduction of cardiovascular risk.

Keywords

cardiovascular risk DPP-4 inhibitors lipid profile meta-analysis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Avogaro A, Giorda C, Maggini M, et al. Diabetes and Informatics Study Group, Association of Clinical Diabetologists, Istituto Superiore di Sanità. Incidence of coronary heart disease in type 2 diabetic men and women: impact of microvascular complications, treatment, and geographic location. Diabetes Care. 2007;30:1241–1247.PubMedCrossRefGoogle Scholar
  2. 2.
    Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580–591.PubMedCrossRefGoogle Scholar
  3. 3.
    American Diabetes Association. Standards of Medical Care in Diabetes 2011. Diabetes Care. 2011;34:S11–S61.CrossRefGoogle Scholar
  4. 4.
    International Diabetes Federation, 2005. Global guideline for type 2 diabetes. Available at: http://www.idf.org/webdata/docs/IDF%20GGT2D.pdf. Accessed December 12, 2011.
  5. 5.
    Associazione Medici Diabetologi — Società Italiana di Diabetologia. Standard Italiani per la cura del diabete mellito. Available at: http://www.siditalia.it/images/Documenti/2010_linee_guida.pdf. Accessed December 12, 2011.
  6. 6.
    Derosa G, Salvadeo SA. Pioglitazone and rosiglitazone: effects of treatment with a thiazolidinedione on lipids and non conventional cardiovascular risk factors. Curr Clin Pharmacol. 2008;3:77–84.PubMedCrossRefGoogle Scholar
  7. 7.
    Wulffelé MG, Kooy A, de Zeeuw D, Stehouwer CD, Gansevoort RT. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. J Intern Med. 2004;256:1–14.PubMedCrossRefGoogle Scholar
  8. 8.
    Rosenstock J, Kim SW, Baron MA, et al. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab. 2007;9:175–185.PubMedCrossRefGoogle Scholar
  9. 9.
    Aschner P, Katzeff HL, Guo H, et al. Sitagliptin Study 049 Group. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes Obes Metab. 2010;12:252–261PubMedCrossRefGoogle Scholar
  10. 10.
    Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–269.PubMedGoogle Scholar
  11. 11.
    Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–1101.PubMedCrossRefGoogle Scholar
  12. 12.
    Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634.PubMedCrossRefGoogle Scholar
  13. 13.
    Schweizer A, Dejager S, Foley JE, Couturier A, Ligueros-Saylan M, Kothny W. Assessing the cardio-cerebrovascular safety of vildagliptin: metaanalysis of adjudicated events from a large Phase III type 2 diabetes population. Diabetes Obes Metab. 2010;12:485–494.PubMedCrossRefGoogle Scholar
  14. 14.
    Taskinen MR, Rosenstock J, Tamminen I, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2011;13:65–74.PubMedCrossRefGoogle Scholar
  15. 15.
    Jadzinsky M, Pfutzner A, Paz-Pacheco E, Xu Z, Allen E, Chen R. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab. 2009;11:611–622.PubMedCrossRefGoogle Scholar
  16. 16.
    Yoon KH, Shockey GR, Teng R, et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes. Int J Clin Pract. 2011;65:154–164.PubMedCrossRefGoogle Scholar
  17. 17.
    DeFronzo RA, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care. 2008;31:2315–2317.PubMedCrossRefGoogle Scholar
  18. 18.
    Pratley RE, Kipnes MS, Fleck PR, Wilson C, Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Obes Metab. 2009;11:167–176.CrossRefGoogle Scholar
  19. 19.
    Hollander P, Li J, Allen E, Chen R. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Meta. 2010;94:4810–4819.CrossRefGoogle Scholar
  20. 20.
    Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebocontrolled, parallel-group study. Clin Ther. 2006; 28:1556–1568.PubMedCrossRefGoogle Scholar
  21. 21.
    Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006; 29:2638–2643.PubMedCrossRefGoogle Scholar
  22. 22.
    Bergenstal RM, Wysham C, Macconell L, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet. 2010;376:431–439.PubMedCrossRefGoogle Scholar
  23. 23.
    Pratley R, Nauck M, Bailey T, et al. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract. 2011;65:397–407.PubMedCrossRefGoogle Scholar
  24. 24.
    Williams-Herman D, Johnson J, Teng R, et al. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes Obes Metab. 2010;12:442–451.PubMedCrossRefGoogle Scholar
  25. 25.
    Dejager S, Razac S, Foley JE, Schweizer A. Vildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm Metab Res. 2007;39:218–223.PubMedCrossRefGoogle Scholar
  26. 26.
    Bolli G, Dotta F, Colin L, Minic B, Goodman M. Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Obes Metab. 2009;11:589–595.PubMedCrossRefGoogle Scholar
  27. 27.
    Schweizer A, Couturier A, Foley JE, Dejager S. Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naive patients with Type 2 diabetes. Diabet Med. 2007;24:955–961.PubMedCrossRefGoogle Scholar
  28. 28.
    Williams-Herman D, Engel SS, Round E, et al. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes BMC Endocr Disord. 2010;10:7.PubMedCrossRefGoogle Scholar
  29. 29.
    Frederich R, Alexander JH, Fiedorek FT, et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med. 2010;122:16–27.PubMedCrossRefGoogle Scholar
  30. 30.
    van Wijk JP, de Koning EJ, Martens EP, Rabelink TJ. Thiazolidinediones and blood lipids in type 2 diabetes. Arterioscler Thromb Vasc Biol. 2003;23:1744–1749.PubMedCrossRefGoogle Scholar
  31. 31.
    Hsieh J, Longuet C, Baker CL, et al. The glucagonlike peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia. 2010;53:552–561.PubMedCrossRefGoogle Scholar
  32. 32.
    Juntti-Berggren L, Pigon J, Karpe F, et al. The antidiabetogenic effect of GLP-1 is maintained during a 7-day treatment period and improves diabetic dyslipoproteinemia in NIDDM patients. Diabetes Care. 1996;19:1200–1206.PubMedCrossRefGoogle Scholar
  33. 33.
    Monami M, Cremasco F, Lamanna C, Marchionni N, Mannucci E. Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials. Diabetes Metab Res Rev. 2011;27:362–372.PubMedCrossRefGoogle Scholar
  34. 34.
    Mannucci E, Rotella CM. Future perspectives on glucagon-like peptide-1, diabetes and cardiovascular risk. Nutr Metab Cardiovasc Dis. 2008;18:639–645.PubMedCrossRefGoogle Scholar
  35. 35.
    Giorgino F, Leonardini A, Natalicchio A, Laviola L. Multifactorial intervention in Type 2 diabetes: the promise of incretin-based therapies. J Endocrinol Invest. 2011;34:69–77.PubMedGoogle Scholar
  36. 36.
    Monami M, Dicembrini I, Martelli D, Mannucci E. Safety of dipeptidyl peptidase-4 inhibitors. A metaanalysis of randomized clinical trials. Curr Med Res Opin. 2011;27:57–64.PubMedCrossRefGoogle Scholar
  37. 37.
    Monami M, Cremasco F, Lamanna C, et al. Glucagon-like Peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. Exp Diabetes Res. 2011; [Epub-ahead of print].Google Scholar

Copyright information

© Springer Healthcare 2011

Authors and Affiliations

  • Matteo Monami
    • 1
  • Caterina Lamanna
    • 2
  • Carla Maria Desideri
    • 2
  • Edoardo Mannucci
    • 2
  1. 1.Section of Geriatric Cardiology and Medicine, Department of Cardiovascular Medicine, CareggiTeaching HospitalFlorenceItaly
  2. 2.Diabetes AgencyCareggi Teaching HospitalFlorenceItaly

Personalised recommendations